WHIP 180
Alternative Names: WHI-P180Latest Information Update: 24 Aug 2010
Price :
$50 *
At a glance
- Originator Wayne Hughes Institute
- Developer Transition Therapeutics; Wayne Hughes Institute
- Class Antiallergics; Antihistamines
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Mast cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Brain cancer; Food hypersensitivity; Urticaria
Most Recent Events
- 15 Mar 2006 Preclinical trials in Brain cancer in Canada (unspecified route)
- 15 Sep 1998 Preclinical development for Allergic rhinitis in USA (Unknown route)
- 15 Sep 1998 Preclinical development for Food allergy in USA (Unknown route)